Biotech firm ANA Therapeutics has begun Phase II / III trial to analyse the safety and efficacy of its oral niclosamide (ANA001) formulation for treating patients with moderate Covid-19.
Months into the COVID-19 pandemic, just three therapeutics have been approved to treat COVID-19: dexamethasone in the United Kingdom and Japan ; Avigan (favilavir) in China , Italy and Russia; and Veklury (remdesivir) in Japan and Australia. Convalescent plasma may be used in the US to treat hospitalized patients under an emergency use authorization (EUA) or an investigational new drug application (IND). “Adequate and well-controlled randomized trials remain ne...
Nottingham-based pharmaceutical services company Quotient Sciences has acquired a 160-strong business which specialises in drug substance, drug product and bioanalysis. The transaction provides an exit for BGF.
ANA Therapeutics News Full Screen View
Market Place
Share